The Watch-PAT 200 system monitors multiple physiologic parameters throughout a sleep study.
Itamar Medical Ltd. (TASE:ITMR) has obtained US Food and Drug Administration (FDA) approval for its Watch-PAT 200 sleep disturbance diagnosis system. The company made the announcement at the Associated Professional Sleep Societies (APSS) conference in Baltimore.
The FDA approved a separate application for the Watch-PAT system earlier this month.
Watch-PAT system records multiple physiologic parameters throughout a sleep study and provides physicians with all parameters required to confirm or rule-out obstructive sleep apnea, including Apnea-Hypopnea Index (AHI), Respiratory Disturbance Index (RDI), Oxygen Desaturation Index (ODI), heart rate, snoring intensity and body position. The system does not require the attachment of EEG electrodes.
Itamar Medical will market the Watch-PAT 200 in the US in addition to the Watch-PAT 100.
Published by Globes [online], Israel business news - www.globes-online.com - on June 12, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008